Soligenix Stock Investor Sentiment

SNGX Stock  USD 3.33  0.01  0.30%   
Slightly above 63% of all Soligenix's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Soligenix suggests that some traders are interested. Soligenix's investing sentiment can be driven by a variety of factors including economic data, Soligenix's earnings reports, geopolitical events, and overall market trends.
  

Soligenix Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Soligenix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at simplywall.st         
Soligenix Full Year 2023 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Yahoo News
over six months ago at seekingalpha.com         
Soligenix GAAP EPS of -0.79
seekingalpha News
over six months ago at investorplace.com         
SNGX Stock Earnings Soligenix Beats EPS, Beats Revenue for Q4 2023
sbwire news
over six months ago at news.google.com         
Soligenix Share Price Crosses Above 200-Day Moving Average of 0.60 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Soligenix Stock Crosses Above 200 Day Moving Average of 0.58 - AmericanBankingNEWS
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Purchase by Christopher Schaber of 7000 shares of Soligenix
Macroaxis News
over six months ago at benzinga.com         
The Antidotes Market Size Is Expected To Reach 3.27 Billion By 2028, At A CAGR Of 10.0 percent As Pe...
benzinga news
over six months ago at thelincolnianonline.com         
Soligenix, Inc. Short Interest Update
news
over six months ago at investing.com         
Soligenix advances Behets Disease treatment study
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Soligenix Announces Formation of Behets Disease Medical Advisory Board
Yahoo News
over six months ago at news.google.com         
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg T...
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Soligenix to Present at The Microcap Conference
Yahoo News
over six months ago at seekingalpha.com         
Soligenix files to sell 10.64M shares of common stock, warrants
seekingalpha News
over six months ago at finance.yahoo.com         
SNGX Phase 2a Psoriasis Trial Achieves Clinical Success
Yahoo News
Far too much social signal, news, headlines, and media speculation about Soligenix that are available to investors today. That information is available publicly through Soligenix media outlets and privately through word of mouth or via Soligenix internal channels. However, regardless of the origin, that massive amount of Soligenix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Soligenix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Soligenix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Soligenix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Soligenix alpha.

Soligenix Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Cote Timothy R. of 15000 shares of Soligenix at 1.42 subject to Rule 16b-3
09/16/2024
2
Soligenix Announces Partnership with Sterling Pharma Solutions
10/03/2024
3
Acquisition by Zeldis Jerome B of 38136 shares of Soligenix at 0.59 subject to Rule 16b-3
10/18/2024
4
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
10/24/2024
5
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 for the treatment of Behets Disease
11/14/2024
6
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
11/26/2024

Additional Tools for Soligenix Stock Analysis

When running Soligenix's price analysis, check to measure Soligenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Soligenix is operating at the current time. Most of Soligenix's value examination focuses on studying past and present price action to predict the probability of Soligenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Soligenix's price. Additionally, you may evaluate how the addition of Soligenix to your portfolios can decrease your overall portfolio volatility.